By using this site, you agree to the Privacy Policy and Terms of Use.
Accept
AmextaFinanceAmextaFinance
  • Home
  • News
  • Banking
  • Credit Cards
  • Loans
  • Mortgage
  • Investing
  • Markets
    • Stocks
    • Commodities
    • Crypto
    • Forex
  • Videos
  • More
    • Finance
    • Dept Management
    • Small Business
9
Notification Show More
Videos
2️⃣ of Buffett’s biggest investing tips this financial adviser follows.
3 hours ago
Videos
Why It Feels Like Every Company Suddenly Wants To Sell You Protein
4 hours ago
News
Deutsche Bank Aktiengesellschaft (DB) Q2 2025 Earnings Call Transcript
7 hours ago
News
Asian automakers’ profits tumble after ‘unprecedented’ effects of US tariffs
13 hours ago
News
The polarising power of Andriy Yermak, Ukraine’s other wartime leader
19 hours ago
Videos
Use buy now, pay later loans? They could soon impact your credit score
1 day ago
Videos
How Airbus beat Boeing to become the world’s biggest plane maker
1 day ago
News
Turning Point Brands: Is This ‘Smokeless’ Stock Too Hot To Touch? (NYSE:TPB)
1 day ago
News
Macrons file US lawsuit over claims France’s first lady was born male
1 day ago
Aa
AmextaFinanceAmextaFinance
Aa
  • Banking
  • Credit Cards
  • Loans
  • Dept Management
  • Mortgage
  • Markets
  • Investing
  • Small Business
  • Videos
  • Home
  • News
  • Banking
  • Credit Cards
  • Loans
  • Mortgage
  • Investing
  • Markets
    • Stocks
    • Commodities
    • Crypto
    • Forex
  • Videos
  • More
    • Finance
    • Dept Management
    • Small Business
Follow US
AmextaFinance > Markets > Stocks > Insulin makers testify on Capitol Hill over prices
Stocks

Insulin makers testify on Capitol Hill over prices

News Room
Last updated: 2023/05/11 at 4:45 PM
By News Room
Share
4 Min Read
SHARE

© Reuters. FILE PHOTO: Boxes of the drug NovoLog, made by Novo Nordisk Pharmaceutical, sit on a counter at a pharmacy in Provo, Utah, U.S. January 9, 2020. REUTERS/George Frey

By Ahmed Aboulenein

WASHINGTON (Reuters) – Leaders of major insulin makers and pharmacy benefit managers (PBMs) traded blame for the life-saving drug’s high price on Wednesday while testifying at a U.S. Senate committee hearing on making it more affordable.

PBMs negotiate with drugmakers for rebates and lower fees on behalf of employers and other clients, and reimburse pharmacies for prescriptions they dispense. Both sides blame each other for high drug prices.

Testifying on Wednesday were the CEOs of major insulin manufacturers Eli Lilly (NYSE:) and Co, Novo Nordisk (NYSE:), and Sanofi (NASDAQ:), which together control 90% of the U.S. market, and top PBM executives from CVS Health Corp (NYSE:), Cigna (NYSE:) Group’s Express Scripts (NASDAQ:), and UnitedHealth Group Inc (NYSE:)’s Optum RX, which control 80% of the prescription drug market.

“Why, in the richest country on Earth, do 1.3 million Americans ration insulin because of the cost? Why are 1 out of 4 Americans not able to afford the prescription drugs their doctors prescribe?” asked Senator Bernie Sanders, who chairs the Senate Health, Education, Labor, and Pensions (HELP) Committee.

The Lilly, Novo Nordisk, and Sanofi CEOs all said drugmakers pay substantial rebates aimed at lowering costs but that PBMs and insurers are incentivized to choose drugs with higher prices because they lead to larger rebates.

“Higher list prices allow for higher fees and rebates, which can increase patients out of pocket costs while benefiting employers, insurance companies and people who don’t use medicines,” Eli Lilly CEO David Ricks said.

PBM executives said manufacturers alone set the drug prices and abuse patent protections to stifle competition. Drug costs would be even higher without the rebates that PBMs negotiate for their customers, Optum Rx CEO Heather Cianfrocco said.

“They count on us to be a counterweight to the substantial market power of manufacturers, which have the sole discretion in setting and raising prices for their products,” she said.

The Lilly, Novo Nordisk, and Sanofi CEOs pointed to their companies cutting list prices by more than 70% for some insulin products in March and said they hoped to provide insulin to more customers a year from now.

The cuts could help around 2 million people pay for insulin. Although many people, including some 3.3 million on Medicare, pay $35 a month or less, about 1-in-5 with private insurance and the 17% of insulin users who are uninsured stand to benefit.

Uninsured people often have to pay full list prices, an average of $900 a month, forcing many to ration or skip doses.

In response to a question from Sanders, the pharmaceutical executives all committed to keep their newest insulin available to patients at $35 a month or less.

Read the full article here

News Room May 11, 2023 May 11, 2023
Share this Article
Facebook Twitter Copy Link Print
Leave a comment Leave a comment

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Finance Weekly Newsletter

Join now for the latest news, tips, and analysis about personal finance, credit cards, dept management, and many more from our experts.
Join Now
2️⃣ of Buffett’s biggest investing tips this financial adviser follows.

Watch full video on YouTube

Why It Feels Like Every Company Suddenly Wants To Sell You Protein

Watch full video on YouTube

Deutsche Bank Aktiengesellschaft (DB) Q2 2025 Earnings Call Transcript

Deutsche Bank Aktiengesellschaft (NYSE:DB) Q2 2025 Earnings Conference Call July 24, 2025…

Asian automakers’ profits tumble after ‘unprecedented’ effects of US tariffs

Stay informed with free updatesSimply sign up to the Automobiles myFT Digest…

The polarising power of Andriy Yermak, Ukraine’s other wartime leader

On the biting morning of December 1 2023, just beyond the eastern…

- Advertisement -
Ad imageAd image

You Might Also Like

Stocks

CPS reports solid 2023 performance, eyes future growth By Investing.com

By News Room
Stocks

Niu Technologies faces mixed results in Q4 2023 By Investing.com

By News Room
Stocks

Exagen Inc. reports strong 2023 revenue growth By Investing.com

By News Room
Stocks

Legacy Housing reports mixed results amid sales decline By Investing.com

By News Room
Stocks

Harmony Biosciences exec sells over $383k in stock By Investing.com

By News Room
Stocks

Biofrontera posts record revenue and outlines growth plans By Investing.com

By News Room
Stocks

Granite Ridge CFO buys $31,000 in company stock By Investing.com

By News Room
Stocks

Coliseum Capital Management buys MasterCraft Boat shares worth over $3.2m By Investing.com

By News Room
Facebook Twitter Pinterest Youtube Instagram
Company
  • Privacy Policy
  • Terms & Conditions
  • Press Release
  • Contact
  • Advertisement
More Info
  • Newsletter
  • Market Data
  • Credit Cards
  • Videos

Sign Up For Free

Subscribe to our newsletter and don't miss out on our programs, webinars and trainings.

I have read and agree to the terms & conditions
Join Community

2023 © Indepta.com. All Rights Reserved.

YOUR EMAIL HAS BEEN CONFIRMED.
THANK YOU!

Welcome Back!

Sign in to your account

Lost your password?